CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Eliseeva, E.
Right arrow Articles by Plon, S. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eliseeva, E.
Right arrow Articles by Plon, S. E.
Cell Growth & Differentiation Vol. 12, 427-433, August 2001
© 2001 American Association for Cancer Research

Expression and Localization of the CDC34 Ubiquitin-conjugating Enzyme in Pediatric Acute Lymphoblastic Leukemia1

Elena Eliseeva, Debananda Pati, Mitchell B. Diccinanni, Alice L. Yu, Syed K. Mohsin, Judith F. Margolin and Sharon E. Plon2

Department of Pediatrics, Texas Children’s Cancer Center, Baylor College of Medicine, Houston, Texas 77030 [E. E., D. P., J. F. M., S. E. P.]; The Breast Center, Baylor College of Medicine, Houston, Texas 77030 [S. K. M.]; and Department of Pediatrics, University of California at San Diego Medical Center, San Diego, California 92103 [M. B. D., A. L. Y.]

Ubiquitin-dependent protein degradation impacts many cellular processes.However, the regulation of ubiquitin-conjugating enzymes (UBCs) in cancer is unknown. We find that the human CDC34 UBC protein is expressed at a 3–4 fold higher level (P < 0.001) in pediatric T cell than in pre-B-cell acute lymphoblastic leukemia (ALL) before treatment in two independent patient sets. The level of CDC34 mRNA was similar in both types of leukemia. CDC34 expression levels in normal resting T cells, B cells and activated T lymphocytes was comparable with pre-B-cell ALL. CDC34 protein (but not mRNA) was also increased in T-cell ALL compared with pre-B-cell ALL cell lines. The difference in expression was not attributable to mutation or associated with altered CDC34 stability. Immunohistochemistry and cellular fractionation reveals a heterogeneous CDC34 expression pattern including cells containing primarily cytoplasmic or nuclear protein. Thus, a feature of pediatric T-cell ALL is posttranscriptional up-regulation and heterogeneous localization of the human CDC34 UBC.




This article has been cited by other articles:


Home page
Mol. Cell. Biol.Home page
K. M. Scaglione, P. K. Bansal, A. E. Deffenbaugh, A. Kiss, J. M. Moore, S. Korolev, R. Cocklin, M. Goebl, K. Kitagawa, and D. Skowyra
SCF E3-Mediated Autoubiquitination Negatively Regulates Activity of Cdc34 E2 but Plays a Nonessential Role in the Catalytic Cycle In Vitro and In Vivo
Mol. Cell. Biol., August 15, 2007; 27(16): 5860 - 5870.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 2001 by the American Association of Cancer Research.